These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 32935100)

  • 1. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles.
    Lu M; Uchil PD; Li W; Zheng D; Terry DS; Gorman J; Shi W; Zhang B; Zhou T; Ding S; Gasser R; Prevost J; Beaudoin-Bussieres G; Anand SP; Laumaea A; Grover JR; Lihong L; Ho DD; Mascola J; Finzi A; Kwong PD; Blanchard SC; Mothes W
    bioRxiv; 2020 Sep; ():. PubMed ID: 32935100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.
    Yang Z; Han Y; Ding S; Shi W; Zhou T; Finzi A; Kwong PD; Mothes W; Lu M
    mBio; 2021 Feb; 13(1):e0322721. PubMed ID: 35164561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational dynamics of SARS-CoV-2 Omicron spike trimers during fusion activation at single molecule resolution.
    Dey S; Pahari P; Mukherjee S; Munro JB; Das DK
    Structure; 2024 Nov; 32(11):1910-1925.e6. PubMed ID: 39366371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction.
    Gobeil S; Janowska K; McDowell S; Mansouri K; Parks R; Manne K; Stalls V; Kopp M; Henderson R; Edwards RJ; Haynes BF; Acharya P
    bioRxiv; 2020 Oct; ():. PubMed ID: 33052347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
    Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
    Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles.
    Lu M; Uchil PD; Li W; Zheng D; Terry DS; Gorman J; Shi W; Zhang B; Zhou T; Ding S; Gasser R; Prévost J; Beaudoin-Bussières G; Anand SP; Laumaea A; Grover JR; Liu L; Ho DD; Mascola JR; Finzi A; Kwong PD; Blanchard SC; Mothes W
    Cell Host Microbe; 2020 Dec; 28(6):880-891.e8. PubMed ID: 33242391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.
    Prévost J; Gasser R; Beaudoin-Bussières G; Richard J; Duerr R; Laumaea A; Anand SP; Goyette G; Benlarbi M; Ding S; Medjahed H; Lewin A; Perreault J; Tremblay T; Gendron-Lepage G; Gauthier N; Carrier M; Marcoux D; Piché A; Lavoie M; Benoit A; Loungnarath V; Brochu G; Haddad E; Stacey HD; Miller MS; Desforges M; Talbot PJ; Maule GTG; Côté M; Therrien C; Serhir B; Bazin R; Roger M; Finzi A
    Cell Rep Med; 2020 Oct; 1(7):100126. PubMed ID: 33015650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.
    Zhang B; Chao CW; Tsybovsky Y; Abiona OM; Hutchinson GB; Moliva JI; Olia AS; Pegu A; Phung E; Stewart-Jones GBE; Verardi R; Wang L; Wang S; Werner A; Yang ES; Yap C; Zhou T; Mascola JR; Sullivan NJ; Graham BS; Corbett KS; Kwong PD
    Sci Rep; 2020 Oct; 10(1):18149. PubMed ID: 33097791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.
    Perreault J; Tremblay T; Fournier MJ; Drouin M; Beaudoin-Bussières G; Prévost J; Lewin A; Bégin P; Finzi A; Bazin R
    Blood; 2020 Nov; 136(22):2588-2591. PubMed ID: 33001206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.
    Ding S; Laumaea A; Benlarbi M; Beaudoin-Bussières G; Gasser R; Medjahed H; Pancera M; Stamatatos L; McGuire AT; Bazin R; Finzi A
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33114742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study.
    Jaiswal V; Nasa P; Raouf M; Gupta M; Dewedar H; Mohammad H; Al Rais Z; Ali Baqer M; Alsabbah A; Ibrahim Y; Salem M; Shammass D; Marashi M
    Int J Infect Dis; 2021 Jan; 102():332-334. PubMed ID: 33157287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate and adaptive immune responses against coronavirus.
    Hosseini A; Hashemi V; Shomali N; Asghari F; Gharibi T; Akbari M; Gholizadeh S; Jafari A
    Biomed Pharmacother; 2020 Dec; 132():110859. PubMed ID: 33120236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
    Lee WT; Girardin RC; Dupuis AP; Kulas KE; Payne AF; Wong SJ; Arinsburg S; Nguyen FT; Mendu DR; Firpo-Betancourt A; Jhang J; Wajnberg A; Krammer F; Cordon-Cardo C; Amler S; Montecalvo M; Hutton B; Taylor J; McDonough KA
    J Infect Dis; 2021 Jan; 223(1):47-55. PubMed ID: 33104179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
    Gemici A; Bilgen H; Erdoğan C; Kansu A; Olmuşçelik O; Beköz HS; Çakmak R; Mert A; Sevindik ÖG
    Turk J Med Sci; 2020 Dec; 50(8):1781-1785. PubMed ID: 33078604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
    Zeng C; Evans JP; Pearson R; Qu P; Zheng YM; Robinson RT; Hall-Stoodley L; Yount J; Pannu S; Mallampalli RK; Saif L; Oltz E; Lozanski G; Liu SL
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33035201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.
    Putter JS; Seghatchian J
    Transfus Apher Sci; 2020 Oct; 59(5):102934. PubMed ID: 32948465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.